**Ionis Pharmaceuticals** is a [biotechnology](https://en.wikipedia.org/wiki/Biotechnology "Biotechnology") company based in [Carlsbad, California](https://en.wikipedia.org/wiki/Carlsbad,_California "Carlsbad, California") that specializes in discovering and developing [RNA](https://en.wikipedia.org/wiki/RNA "RNA")-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza ([Nusinersen](https://en.wikipedia.org/wiki/Nusinersen "Nusinersen")), Tegsedi ([Inotersen](https://en.wikipedia.org/wiki/Inotersen "Inotersen")), and Waylivra ([Volanesorsen](https://en.wikipedia.org/wiki/Volanesorsen "Volanesorsen")) and has 4 drugs in pivotal studies: tominersen for [Huntington’s disease](https://en.wikipedia.org/wiki/Huntington%E2%80%99s_disease "Huntington’s disease"), tofersen for SOD1-[ALS](https://en.wikipedia.org/wiki/ALS "ALS"), AKCEA-APO(a)-LRx for [cardiovascular disease](https://en.wikipedia.org/wiki/Cardiovascular_disease "Cardiovascular disease"), and AKCEA-TTR-LRx for all forms of TTR [amyloidosis](https://en.wikipedia.org/wiki/Amyloidosis "Amyloidosis"). The company was named **Isis Pharmaceuticals** until December 2015. [Home Page](https://www.ionispharma.com/)